Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Weighted Average and Diluted) (2019 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.27 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 145.45% to $0.27 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.91, a 464.0% increase, with the full-year FY2025 number at $0.75, up 225.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.27 in Q1 2026 for Kiniksa Pharmaceuticals International, up from $0.18 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.18 in Q3 2022 to a low of -$0.36 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.05 (2022), compared with a mean of $0.19.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 822.73% in 2022 and later plummeted 133.33% in 2024.
  • Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) stood at $0.05 in 2022, then soared by 620.0% to $0.36 in 2023, then crashed by 133.33% to -$0.12 in 2024, then soared by 250.0% to $0.18 in 2025, then surged by 50.0% to $0.27 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.27 (Q1 2026), $0.18 (Q4 2025), and $0.23 (Q3 2025) per Business Quant data.